Display options
Share it on

Adv Hematol. 2016;2016:5437609. doi: 10.1155/2016/5437609. Epub 2016 Feb 23.

Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan.

Advances in hematology

Sadia Sultan, Syed Mohammed Irfan, Syed Ijlal Ahmed

Affiliations

  1. Department of Hematology & Blood Bank, Liaquat National Hospital and Medical College, Karachi, Pakistan.
  2. Liaquat National Medical College, Karachi, Pakistan.

PMID: 27006658 PMCID: PMC4783526 DOI: 10.1155/2016/5437609

Abstract

Objectives. Skeletal complications in β-homozygous thalassemic patients are uncommon but often debilitating, even amongst children and adolescent patients with well maintained transfusion and chelation therapy. The aim is to evaluate the biochemical markers of bone turnover in regularly transfused thalassemic patients and its possible correlations with demographic data and hematological and biochemical markers. Methods. In this prospective cross-sectional study, 36 β-thalassemia major patients were enrolled from March 2012 to March 2014. All patients underwent complete blood counts, LFTs, serum ferritin, serum calcium, phosphorus, serum albumin, alkaline phosphatase, 25-OH vitamin D, and parathormone (PTH) levels. Results. There were 17 males and 19 females with mean age of 12.56 ± 5.9 years. Hypocalcemia and hypophosphatemia were seen in 66.6% and 19.4%, respectively, while 25-OH vitamin D deficiency was present in 72.2% of thalassemic children and adolescents. Hypoparathyroidism was seen in 13.8% while hyperparathyroidism was detected in 8.3% of patients. There was direct correlation between serum phosphorus and ferritin levels (P < 0.05). No correlation was found between indirect bilirubin and skeletal parameters, calcium and parathyroid hormone (P > 0.05). Conclusions. Biochemical profile is significantly altered in patients with β-thalassemia major and bone associated biochemical abnormalities like hypocalcaemia, 25-OH vitamin D deficiency, and hypophosphatemia are not uncommon in Pakistani patients with thalassemia major.

References

  1. Int J Endocrinol. 2012;2012:573298 - PubMed
  2. J Pediatr Hematol Oncol. 2002 May;24(4):291-3 - PubMed
  3. J Pediatr Endocrinol Metab. 2002 Nov-Dec;15(9):1531-5 - PubMed
  4. Clin Chem. 1981 Jan;27(1):204-5 - PubMed
  5. Arch Dis Child. 1978 Apr;53(4):347-8 - PubMed
  6. Hematology. 2006 Jun;11(3):197-202 - PubMed
  7. Metabolism. 1998 May;47(5):541-8 - PubMed
  8. Saudi Med J. 2004 Oct;25(10):1347-51 - PubMed
  9. J Pak Med Assoc. 2012 Mar;62(3):307-10 - PubMed
  10. J Bone Miner Metab. 2006;24(2):138-45 - PubMed
  11. J Bone Miner Metab. 2013 Jul;31(4):468-76 - PubMed
  12. Eur J Pediatr. 1986 Apr;145(1-2):133-6 - PubMed
  13. Int J Hematol Oncol Stem Cell Res. 2013;7(4):10-4 - PubMed
  14. Ann Saudi Med. 2000 Sep-Nov;20(5-6):364-6 - PubMed
  15. Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:149-54 - PubMed
  16. Malays J Pathol. 2015 Apr;37(1):35-8 - PubMed
  17. BMC Endocr Disord. 2003 Aug 12;3(1):4 - PubMed
  18. Ann N Y Acad Sci. 2005;1054:462-6 - PubMed
  19. Sultan Qaboos Univ Med J. 2007 Dec;7(3):215-8 - PubMed
  20. Bone. 2011 Oct;49(4):819-23 - PubMed
  21. Int J Clin Pract. 2005 Jan;59(1):46-51 - PubMed
  22. J Bone Miner Metab. 2004;22(1):53-7 - PubMed
  23. Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S23-30 - PubMed
  24. Br J Haematol. 2009 Sep;146(5):546-56 - PubMed
  25. Bone. 2006 Jun;38(6):888-92 - PubMed

Publication Types